mailitics

Category: Vertex

  • STAT+: Scientists who revolutionized cystic fibrosis treatment win prestigious Lasker Award

    STAT+: Scientists who revolutionized cystic fibrosis treatment win prestigious Lasker Award Three scientists who revolutionized the treatment of cystic fibrosis and prolonged the lifespan of patients with the deadly disease have won the Lasker Award, one of the most prestigious awards in medicine. Vertex Pharmaceuticals researcher Paul Negulescu, former Vertex researcher Jesús (Tito) González, and…

  • Closing a zombie biotech, and Lilly’s disappointing obesity readout

    Closing a zombie biotech, and Lilly’s disappointing obesity readout How does a biotech company decide to shut itself down? Why does Eli Lilly have so much riding on its oral obesity candidate? And what’s the outlook for Vertex’s pain franchise? We discuss that and more on this on this week’s episode of “The Readout LOUD,”…

  • STAT+: Vertex next-generation pain candidate fails Phase 2 trial

    STAT+: Vertex next-generation pain candidate fails Phase 2 trial Vertex Pharmaceuticals said Monday afternoon that its next-generation non-opioid pain reliever failed to significantly outperform placebo in a Phase 2 trial. The experimental drug, codenamed VX-993, is similar to the company’s recently approved pill Journavx but could potentially be given at higher doses and formulated as…

  • STAT+: Off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results

    STAT+: Off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results Twelve people with type 1 diabetes who received an investigational off-the-shelf stem cell therapy were able to produce their own insulin and keep healthy blood glucose levels for at least one year, Vertex Pharmaceuticals said Friday. After three months, none of…

  • STAT+: Vertex reports an earnings miss and pause on cystic fibrosis trial

    STAT+: Vertex reports an earnings miss and pause on cystic fibrosis trial Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene therapy for sickle cell disease and a recently launched pain medicine.  A “tolerability issue” caused a temporary…